BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:55 PM
 | 
Oct 23, 2007
 |  BC Extra  |  Clinical News

Treanda meets NHL endpoints

Cephalon (CEPH) said Treanda bendamustine met the co-primary endpoints of overall response rate and a median duration of response in a Phase III trial in 100 patients with relapsed, rituximab-refractory, indolent non-Hodgkin's lymphoma...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >